Dental Care Clinics in Isabela, PR Accepting Medicare
6 Dental Care Clinics found. Showing 1 - 6
 Vkt Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: Calle Barbosa #5, Suite #1, Isabela, PR 00662 Phone: 787-872-2046 |
Isabela Dental Clinic Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: Ave. Juan Hernandez Ortiz, Centro Comercial Coop Ofic 205, Isabela, PR 00662 Phone: 787-872-3560 Fax: 787-872-3560 |
Lamela Dental Clinic Corp Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 36 Calle Barbosa, Isabela, PR 00662 Phone: 787-872-0005 |
Yvr Servicios Dentales Csp Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 469 Calle Caleta, Calle Don Chemary #86 Moca Pr, Isabela, PR 00662 Phone: 787-877-1701 Fax: 787-877-1701 |
Quintana Serrano Dental, Inc Dentist Medicare: Not Enrolled in Medicare Practice Location: 5 Calle Barbosa, Suite 1, Isabela, PR 00662 Phone: 787-872-2046 Fax: 787-830-5984 |
J&adentalpsc Dentist Medicare: Not Enrolled in Medicare Practice Location: 2981 Ave Militar Ste 1, Isabela, PR 00662 Phone: 787-830-2060 Fax: 787-830-2253 |
News Archive
University of Greenwich hosts conference to address health and social care challenges
In collaboration with the Higher Education Entrepreneurship Group (HEEG), the University of Greenwich is hosting an event to support people with ideas for tackling the current unemployment, enterprise finance and health and social care challenges.
Pacific Biomarkers announces second-quarter fiscal 2010 results
Pacific Biomarkers, Inc., a leading provider of specialized biomarker and contract research services, today announced its operating results for the second quarter and first half of FY2010.
Somaxon awarded $245,000 grant for Silenor under QTDP program
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
Genetic testing not cost-effective in guiding initial dosing of blood-thinner warfarin
New analyses led by the University of Cincinnati (UC) show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding.
› Verified 9 days ago